Based on current trial timelines, retatrutide is not expected to receive FDA approval for weight loss before Q1-Q2 2028 at the earliest. Eli Lilly has not yet submitted a New Drug Application for retatrutide for obesity specifically. The TRIUMPH-1 Phase 3 trial data was published in 2026, and FDA review typically takes 12-18 months after submission. Until then, tirzepatide (Zepbound) remains the most potent FDA-approved option, producing approximately 22% average weight loss in the SURMOUNT trials.
For most people, waiting 18+ months for a drug that produces ~2% more average weight loss than the already-available alternative is not strategically sound. The compounding effect of 12-18 months of weight loss on tirzepatide starting now will likely outpace any marginal benefit from waiting for retatrutide. Additionally, individual response to GLP-1 medications varies significantly — a strong responder on tirzepatide may outperform the retatrutide average anyway.
The exception: if you have tried tirzepatide and found it underperformed, or have significant insulin resistance suggesting a triple-agonist mechanism might help, discussing retatrutide with your physician when it becomes available is a reasonable future option.
Tirzepatide already activates two of retatrutide's three receptor pathways. This is the closest comparison in the GLP-1 medication landscape — here's exactly what the third pathway adds, and why tirzepatide is still the right choice today.
Of all the GLP-1 medication comparisons, this is the most mechanistically interesting one. Tirzepatide and retatrutide share two of their three receptor targets — making this less of a "different drug" comparison and more of a "what does one additional mechanism add" question.
| Receptor | Tirzepatide | Retatrutide |
|---|---|---|
| GLP-1 | ✓ Activated | ✓ Activated |
| GIP | ✓ Activated | ✓ Activated |
| Glucagon | ✗ Not activated | ✓ Activated |
That third receptor — glucagon — is the entire difference between these two medications. Glucagon receptor activation increases energy expenditure and promotes fat oxidation directly, independent of appetite suppression. It's an additive mechanism on top of everything tirzepatide already does.
The roughly 6-percentage-point gap between the two is a meaningful real-world difference — but it's also the smallest gap of any retatrutide comparison, precisely because tirzepatide already covers two-thirds of retatrutide's mechanism.
| Factor | Tirzepatide | Retatrutide |
|---|---|---|
| Receptors activated | GLP-1 + GIP (dual) | GLP-1 + GIP + Glucagon (triple) |
| Avg weight loss | ~22% | 28.3% |
| FDA approved | Yes (2022) | No |
| Legally available | Yes — brand + compounded | No |
| Safety track record | 4+ years real-world use | Trial-only data |
| Monthly cost | ~$149/mo compounded | Not yet priced |
| Available today? | Yes | No — ~2028 estimated |
This is the real question search volume suggests people are asking. Here's the honest math: tirzepatide is available today and produces excellent, well-documented results (~22% average weight loss — already exceeding semaglutide and approaching bariatric-surgery-adjacent territory for many patients). Retatrutide might add another 5-6 percentage points, but isn't accessible until 2028 at the earliest.
Starting tirzepatide today and achieving 22% weight loss over the next 12-18 months is a dramatically better outcome than waiting 24+ months for a medication that might produce 28%. If retatrutide is approved while you're already established on tirzepatide, switching at that point — with an established baseline of weight loss and metabolic improvement already achieved — is a reasonable future option. Waiting now is not.
Once retatrutide is approved, it's likely many patients will simply transition from tirzepatide directly to retatrutide rather than using both, since retatrutide's mechanism is a superset of tirzepatide's. There's no current clinical pathway or evidence for combining them simultaneously, and doing so outside of a clinical trial would carry unknown risk.
DirectMeds offers physician-supervised compounded tirzepatide from $149/month — the dual-mechanism medication that already covers two-thirds of retatrutide's pathway, available right now.
Check tirzepatide eligibility →